Siemens has published a new study which highlights the potential advantages offered by its RAPIDLab 1245 blood gas system.
The medical technology firm has conducted a study for its publication Perspectives, which demonstrates the device's effectiveness in conducting whole blood total bilirubin analysis among newborn children.
It said that the system delivered more accurate and precise results than a leading alternative device, which indicates the RAPIDLab 1245's worth as a means of monitoring potentially dangerous bilirubin levels.
Siemens stated that this represents an important step in neonatal care, as high levels of unconjugated bilirubin circulating in the blood can lead to neurological damage, cerebral palsy or hearing and vision problems if left untreated.
"Analysis of unhaemolysed whole blood using the RAPIDLab 1245 or RAPIDLab 1265 is a clinically acceptable method for monitoring the development of pathologic concentrations of bilirubin in neonates," added the manufacturer.
Last month, Siemens received a recommendation from the International Federation for Clinical Chemistry for its DCA Vantage diabetes analyser to provide dual reporting functions.See all the latest jobs in Medical Devices